INTI · Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics provided a detailed update on its lead program targeting surgically eligible basal cell carcinomas in Gorlin Syndrome (BCCNS) using repurposed itraconazole. The ongoing three-way crossover PK study in healthy volunteers under fasting conditions in Malaysia is advancing as planned, with key dosing milestones in Period 2 (April 10, 2026) and Period 3 (April 24, 2026), followed by sample shipment around May 1, 2026, and top-line results shortly thereafter. This study, conducted with Avior Bio, supports the FDA 505(b)(2) regulatory pathway and is positioned as the final clinical requirement prior to NDA submission, representing a critical de-risking step for the program. The Company's amorphous formulation addresses itraconazole's known solubility challenges, aiming for improved absorption and consistency, as evidenced in the IMPD with X-ray diffraction confirming amorphous structure. In parallel, Inhibitor plans a global patent filing on the formulation composition, potentially bolstering IP protection without royalties and enhancing asset value for commercialization or partnerships. This progress underscores steady execution in a rare disease indication with significant unmet need, where patients face lifetime BCCs and repeated surgeries.